Cormedix Stock Performance
| CRMD Stock | USD 10.76 0.02 0.19% |
CorMedix has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.61, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CorMedix's returns are expected to increase less than the market. However, during the bear market, the loss of holding CorMedix is expected to be smaller as well. CorMedix right now shows a risk of 4.23%. Please confirm CorMedix sortino ratio, semi variance, rate of daily change, as well as the relationship between the value at risk and kurtosis , to decide if CorMedix will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in CorMedix are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain primary indicators, CorMedix may actually be approaching a critical reversion point that can send shares even higher in December 2025. ...more
| Begin Period Cash Flow | 43.8 M | |
| Total Cashflows From Investing Activities | 21.2 M | |
| Free Cash Flow | -50.7 M |
CorMedix Relative Risk vs. Return Landscape
If you would invest 1,007 in CorMedix on August 11, 2025 and sell it today you would earn a total of 69.00 from holding CorMedix or generate 6.85% return on investment over 90 days. CorMedix is currently generating 0.1862% in daily expected returns and assumes 4.228% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than CorMedix, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CorMedix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CorMedix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CorMedix, and traders can use it to determine the average amount a CorMedix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.044
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CRMD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.23 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average CorMedix is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CorMedix by adding it to a well-diversified portfolio.
CorMedix Fundamentals Growth
CorMedix Stock prices reflect investors' perceptions of the future prospects and financial health of CorMedix, and CorMedix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CorMedix Stock performance.
| Return On Equity | 0.38 | |||
| Return On Asset | 0.2 | |||
| Profit Margin | 0.42 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 672.27 M | |||
| Shares Outstanding | 78.35 M | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 3.91 X | |||
| Price To Sales | 6.94 X | |||
| Revenue | 43.47 M | |||
| EBITDA | (18.83 M) | |||
| Cash And Equivalents | 64.62 M | |||
| Cash Per Share | 1.57 X | |||
| Total Debt | 517.01 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 2.96 X | |||
| Cash Flow From Operations | (50.61 M) | |||
| Earnings Per Share | 0.78 X | |||
| Total Asset | 118.85 M | |||
| Retained Earnings | (339.63 M) | |||
| Current Asset | 37.06 M | |||
| Current Liabilities | 3.06 M | |||
About CorMedix Performance
By analyzing CorMedix's fundamental ratios, stakeholders can gain valuable insights into CorMedix's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CorMedix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CorMedix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. Cormedix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.Things to note about CorMedix performance evaluation
Checking the ongoing alerts about CorMedix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CorMedix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CorMedix had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 43.47 M. Net Loss for the year was (17.93 M) with profit before overhead, payroll, taxes, and interest of 116.16 M. | |
| CorMedix currently holds about 64.62 M in cash with (50.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57. |
- Analyzing CorMedix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CorMedix's stock is overvalued or undervalued compared to its peers.
- Examining CorMedix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CorMedix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CorMedix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CorMedix's stock. These opinions can provide insight into CorMedix's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CorMedix Stock analysis
When running CorMedix's price analysis, check to measure CorMedix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CorMedix is operating at the current time. Most of CorMedix's value examination focuses on studying past and present price action to predict the probability of CorMedix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CorMedix's price. Additionally, you may evaluate how the addition of CorMedix to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |